Skip to main content

Advertisement

SpringerLink
Log in

Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The treatment of Alzheimer’s disease is of increasing importance as the population ages and the number of people with the disease increases. The aetiology of Alzheimer’s disease is complex and therefore treatment strategies rely on generalised pathological findings. Cholinesterase inhibitors enhance a generalised deficit of central nervous system acetylcholine and are the first class of agents specifically approved for the treatment of Alzheimer’s disease.

The clinical efficacy of the different cholinesterase inhibitors is similar; however, differences in pharmacodynamic and pharmacokinetic parameters can influence tolerability and safety in the elderly population. Concomitant disease states, significant drug interactions and the altered kinetics and dynamics seen in elderly patients can also affect treatment outcome.

Although cholinesterase inhibitors are not ‘curative’ for Alzheimer’s disease, clinical evidence indicates that these drugs can significantly delay the progress of cognitive impairment. Consequently, they represent a useful treatment for the symptoms of Alzheimer’s disease in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Eggert A, Crismon ML, Ereshefsky L. Alzheimer’s disease. In: Dipiro J, Talbet RL, Yee GC, et al., editors. Pharmacotherapy. 3rd ed. New York: Elsiever, 1997: 1325–44

    Google Scholar 

  2. Brawn LA, Castleden CM. Adverse drug reactions: an overview of special considerations in the management of the elderly patient. Drug Saf 1990; 5(6): 421–35

    Article  PubMed  CAS  Google Scholar 

  3. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35(1): 49–64

    Article  PubMed  CAS  Google Scholar 

  4. Catterson ML, Preskorn SH, Martin RL. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 1997; 20(1): 205–18

    Article  PubMed  CAS  Google Scholar 

  5. Crismon ML. Tacrine: the first drug approved for Alzheimer’s disease. Ann Pharmacother 1994; 28: 744–51

    PubMed  CAS  Google Scholar 

  6. Rogers SL, Doody RS, Mohs RC, the Donepezil Study Group, et al. Donepezil improves the cognition and global function in Alzheimer’s disease: a 15-week, double-blind, placebocontrolled study. Arch Intern Med 1998; 58: 1021–31

    Article  Google Scholar 

  7. Rainer M. Galanthamine in Alzheimer’s disease: a new alternative to tacrine? CNS Drugs 1997; 7(2): 89–97

    Article  CAS  Google Scholar 

  8. Polinsky RJ. Clinical pharmacology of rivastigmine: a newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther 1998; 20(4): 634–47

    Article  PubMed  CAS  Google Scholar 

  9. Unni LK, Hutt V, Imbimbo BP, et al. Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol 1991; 41: 83–4

    Article  PubMed  CAS  Google Scholar 

  10. Jann MW. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998; 18 (2 Pt 2); 55–67S

    PubMed  CAS  Google Scholar 

  11. Rowland M, Tozer TN. Elimination. In: Clinical pharmacokinetics: concepts and applications. 2nd ed. Malvern (PA): Lea & Febiger, 1989: 148–76

    Google Scholar 

  12. Williams L, Lowenthal DT. Drug therapy in the elderly. South Med J 1992; 85(2): 127–31

    Article  PubMed  CAS  Google Scholar 

  13. Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70: 685–93

    Article  PubMed  CAS  Google Scholar 

  14. O’Connell MB, Dwindell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992; 26: 627–35

    PubMed  Google Scholar 

  15. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19(6): 465–80

    Article  PubMed  CAS  Google Scholar 

  16. Auteri A, Mosca A, Lattuada N, et al. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 1993; 45(4): 373–6

    Article  PubMed  CAS  Google Scholar 

  17. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086–91

    PubMed  CAS  Google Scholar 

  18. Schran HF, Habucky K, Mancione LC, et al. The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase (AChE) inhibitor SDX ENA 713 [abstract]. Pharmacol Res 1996; 13: S428

    Google Scholar 

  19. Tiseo PJ, Varga R, Perdomo CA, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 51–5

    PubMed  CAS  Google Scholar 

  20. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 56–60

    PubMed  CAS  Google Scholar 

  21. Parke-Davis. Cognex (tacrine hydrochloride): prescribing information. Morris Plains (NJ): Parke-Davis, 1993

    Google Scholar 

  22. Masters CL, Beyreuther K. Alzheimer’s disease. BMJ 1998; 316: 446–8

    Article  PubMed  CAS  Google Scholar 

  23. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 1993; 16: 460–5

    Article  PubMed  CAS  Google Scholar 

  24. Iqbal K, Alonso AC, Gong CX, et al. Alzheimer neurofibrillary degeneration: a feasible and key target for therapeutics. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 31–6

    Google Scholar 

  25. Vogel G. Tau protein mutations confirmed as neuron killers. Science 1998; 280: 1524–5

    Article  PubMed  CAS  Google Scholar 

  26. Cordell B. β-Amyloid formation as a potential therapeutic target for Alzheimer’s disease. Annu Rev Pharmacol Toxicol 1994; 34: 69–89

    Article  PubMed  CAS  Google Scholar 

  27. Selkoe D. Amyloid protein and Alzheimer’s disease. Sci Am 1991; 265: 68–78

    Article  PubMed  CAS  Google Scholar 

  28. Oltersdorf T, Fritz LC, Schen DB, et al. The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is the protease nexin-II. Nature 1989; 341: 144–7

    Article  PubMed  CAS  Google Scholar 

  29. Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor Xia-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126–8

    Article  PubMed  CAS  Google Scholar 

  30. Qiu WQ, Ferreira A, Miller C, et al. Cell-surface β-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci 1995; 15: 2157–67

    PubMed  CAS  Google Scholar 

  31. Saitoh T, Sundsmo M, Roch JM, et al. Secreted form of amyloid α protein precursor is involved in the growth regulation of fibroblasts. Cell 1989; 58: 615–22

    Article  PubMed  CAS  Google Scholar 

  32. Mattson MP, Cheng B, Culwell AR, et al. Evidence for excitoprotective and intraveuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10: 243–54

    Article  PubMed  CAS  Google Scholar 

  33. Geerts H, Nuydens R, de Jong M, et al. A new focus on cytoskeletal therapy in Alzheimer’s disease. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 61–5

    Google Scholar 

  34. Chevallier N, Marambaud P, Vincent JP, et al. Novel cathepsin D inhibitors prevent the β-secretase-derived intracellular formation of a 12 kDa potentially amyloidogenic product in human cells. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 67–73

    Google Scholar 

  35. Cacabelos R, Hofman A, Mullan M, et al. Alzheimer’s disease: scientific progress for future trends. DN&P 1993; 6: 242–4

    Google Scholar 

  36. Cacabelos R, Nordberg A, Caamaño J, et al. Therapeutic strategies in Alzheimer’s disease. Ann Psychiatry 1995; 4: 221–79

    Google Scholar 

  37. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry 1994; 151: 1105–13

    PubMed  CAS  Google Scholar 

  38. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876–83

    Article  PubMed  CAS  Google Scholar 

  39. Young AB, Penney JB. Neurotransmitter receptors in Alzheimer’s disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer’s disease. New York (NY): Raven Press, 1994: 293–303

    Google Scholar 

  40. Steele CD, Steinberg M, Milles G, et al. Recognition and management of early Alzheimer’s disease. J Clin Outcomes Manage 1999; 6(3): 52–68

    Google Scholar 

  41. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer’s disease. Drugs 1997; 53(3): 752–68

    Article  PubMed  CAS  Google Scholar 

  42. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9

    Article  PubMed  CAS  Google Scholar 

  43. Knapp MJ, Knopman DS, Soloman PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91

    Article  PubMed  CAS  Google Scholar 

  44. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, doubleblind, placebo-controlled, trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45

    Article  PubMed  CAS  Google Scholar 

  45. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65

    CAS  Google Scholar 

  46. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–40

    Article  PubMed  CAS  Google Scholar 

  47. Cummings JL, Cyrus PA, Bierber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer’s disease: the Metrifonate Study Group. Neurology 1998; 50: 1214–21

    Article  PubMed  CAS  Google Scholar 

  48. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998; 50: 1222–30

    Article  PubMed  CAS  Google Scholar 

  49. Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer’s disease. Neurology 1996; 47: 1389–95

    Article  PubMed  CAS  Google Scholar 

  50. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 1997; 278(16): 1363–71

    Article  PubMed  CAS  Google Scholar 

  51. Food, Drug and Cosmetic Reports. FDA guidance on Alzheimer’s drug clinical utility assessments. FDC Rep 1992: 13–5

  52. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebocontrolled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327: 1253–9

    Article  PubMed  CAS  Google Scholar 

  53. Kluger A, Ferris H. Scales for the assessment of Alzheimer’s disease. Psychiatr Clin North Am 1991; 14(2): 309–26

    PubMed  CAS  Google Scholar 

  54. Morgan CD, Baade LE. Neuropsychological testing and assessment scales for dementia of the Alzheimer’s type. Psychiatr Clin North Am 1997; 20(1): 25–43

    Article  PubMed  CAS  Google Scholar 

  55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64

    PubMed  CAS  Google Scholar 

  56. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer’s disease. J Neural Transm 1991; Suppl. 33: 59–63

    Google Scholar 

  57. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled study of the efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer’s type. Neurobiol Aging 1996; 17 Suppl. 4: S144

    Article  Google Scholar 

  58. Knopman DS, Knapp MJ, Gracon SI, et al. The clinician interview based impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994; 44: 2315–21

    Article  PubMed  CAS  Google Scholar 

  59. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9: 1–6

    PubMed  CAS  Google Scholar 

  60. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 Suppl. 6: S10–16

    Article  PubMed  CAS  Google Scholar 

  61. Riter RN, Fries BE. Predictors of the placement of cognitively impaired residents on special care units. Gerontologist 1992; 32: 184–90

    Article  PubMed  CAS  Google Scholar 

  62. DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11(4): 545–54

    PubMed  CAS  Google Scholar 

  63. Cutler NR, Sramek JJ. The bridging study: optimizing the dose for phase II/III. In: Becker R, Giacobini E, et al. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 387–91

    Google Scholar 

  64. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate in patients with Alzheimer’s disease: results of a maximum tolerated dose study. Life Sci 1998; 62(16): 1433–41

    Article  PubMed  CAS  Google Scholar 

  65. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7

    PubMed  CAS  Google Scholar 

  66. Ford JM, Truman CA, Wilcock GK, et al. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer’s disease. Clin Pharmacol Ther 1993; 53: 691–5

    Article  PubMed  CAS  Google Scholar 

  67. Rogers SL, Cooper NM, Sukavaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HC1 following multiple oral doses. Br J Pharmacol 1998; 46 Suppl. 1: 7–12

    CAS  Google Scholar 

  68. Cutler NR, Anand R, Hartman RD, et al. Antiemetic therapy for Alzheimer’s patients receiving the cholinesterase inhibitor SDZ ENA 713 [abstract]. Clin Pharmacol Ther 1998; 63(2): 188

    Google Scholar 

  69. Sarin S, Gill KD. Biochemical and behavioral deficits in adult rat following chronic dichlorvos exposure. Pharmacol Biochem Behav 1998; 59(4): 1081–6

    Article  PubMed  CAS  Google Scholar 

  70. Glynn P, Holton JL, Nolan CC, et al. Neuropathy target esterase: immunolocalization to neuronal cell bodies and axons. Neuroscience 1998; 83(1): 295–302

    Article  PubMed  CAS  Google Scholar 

  71. Ehrich M, Correll L, Veronesi B. Acetylcholinesterase and neuropathy target esterase inhibitions in neuroblastoma cells to distinguish organophosphorus compounds causing acute and delayed neurotoxicity. Fundam Appl Toxicol 1997; 38(1): 55–63

    Article  PubMed  CAS  Google Scholar 

  72. Fournier L, Musard D, Lecorsier A. Lymphocyte esterases and hydroxylases in neurotoxicology. Vet Hum Toxicol 1996; 38(3): 190–5

    PubMed  CAS  Google Scholar 

  73. Sterri SH, Lyngaas S, Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in guinea-pig and mouse. Acta Pharmacol Toxicol (Copenh) 1981; 49: 8–13

    Article  CAS  Google Scholar 

  74. Williams FM, Charlton C, de Blaquiere GE, et al. The effects of multiple low doses of organophosphates on target enzymes in brain and diaphragm in the mouse. Hum Exp Toxicol 1997; 16: 67–71

    Article  PubMed  CAS  Google Scholar 

  75. Mennear JH. Dichlorvos carcinogenicity: an assessment of the weight of experimental evidence. Regul Toxicol Pharmacol 1994; 20 (3 Pt 1): 354–61

    Article  PubMed  CAS  Google Scholar 

  76. Anonymous. Bayersuspends metrifonate trials. Scrip 1998 Sep 30; 2374: 19

    Google Scholar 

  77. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–8

    Article  PubMed  CAS  Google Scholar 

  78. Chan PC, Huff J, Haseman JK, et al. Carcinogenesis studies of dichlorvos in Fischer rats and B6C3F1 mice. Jpn J Cancer Res 1991; 82(2): 157–64

    Article  PubMed  CAS  Google Scholar 

  79. Blair D, Dix KM, Hunt PF, et al. Dichlorvos: a two-year inhalation carcinogenesis study in rats. Arch Toxicol 1976: 281–94

    Google Scholar 

  80. Zeiger E, Erexson G, Mortelmans K, et al. Genetic toxicity studies of 1,2,3,4-tetrahydro-9-acridinamine (tacrine). Mutat Res 1997; 393(3): 189–97

    Article  PubMed  CAS  Google Scholar 

  81. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12(6): 485–94

    Article  PubMed  CAS  Google Scholar 

  82. Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer’s disease. Pharmacotherapy 1998; 18 (2 Pt 2): 47–54S

    PubMed  CAS  Google Scholar 

  83. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619–27

    Article  PubMed  CAS  Google Scholar 

  84. Becquemont L, Le Bot MA, Riche C, et al. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101–8

    Article  PubMed  CAS  Google Scholar 

  85. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112

    PubMed  CAS  Google Scholar 

  86. Welty D, Pool W, Woolf T, et al. The effect of smoking on the pharmacokinetics and metabolism of Cognex® in healthy volunteers [abstract]. Pharmacol Res 1993; 10: S334

    Google Scholar 

  87. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 30–4

    PubMed  CAS  Google Scholar 

  88. Tiseo PJ, Rogers SL, Perdomo CA, et al. The effect of cimetidine and ketoconazole on the pharmacokinetics of donepezil HCl [abstract]. Clin Pharmacol Ther 1998; 63(2): 234

    Google Scholar 

  89. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25–9

    PubMed  CAS  Google Scholar 

  90. Eisai Inc. Aricept (donepezil hydrochloride): prescribing information. Teaneck (NJ): Eisai Inc., 1998

    Google Scholar 

  91. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46 Suppl. 1: 40–4

    PubMed  CAS  Google Scholar 

  92. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46 Suppl. 1: 35–9

    PubMed  CAS  Google Scholar 

  93. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46 Suppl. 1: 45–50

    PubMed  CAS  Google Scholar 

  94. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact on delaying disease onset. Am J Public Health 1998; 88: 1337–42

    Article  PubMed  CAS  Google Scholar 

  95. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997; 11(6): 490–6

    Article  PubMed  CAS  Google Scholar 

  96. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer’s disease. J Clin Pharmacol 1998; 38: 236–45

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA

    Chad M. VanDen Berg, Yusuf Kazmi &  Michael W. Jann

Authors
  1. Chad M. VanDen Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuf Kazmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael W. Jann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

VanDen Berg, C.M., Kazmi, Y. & Jann, M.W. Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease in the Elderly. Drugs & Aging 16, 123–138 (2000). https://doi.org/10.2165/00002512-200016020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200016020-00004

Keywords

Search

Navigation